Find More Contacts for Kuros Biosciences
Protected Content
Health Professional
Director
1 email found
View contacts for Kuros Biosciences to access new leads and connect with decision-makers.
View All Contacts
  • Contact Email info@kuros.ch
  • Phone Number 41 44 200 56 00

Kuros Biosciences AG is a Swiss-based company focused on the development of innovative products for tissue repair and regeneration.

Founded in 2000 as a spin-off of the Eidgenössische Technische Hochschule Zürich (ETHZ), Kuros has developed a pipeline of products based upon its proprietary technology platforms. These platforms were developed from

work carried out at ETHZ, at the University of Zürich and at the California Institute of Technology (CalTech). In addition, in early 2017 Kuros acquired Xpand Biotechnology to gain access to its MagnetOs family of bone graft substitutes and the associated surface science technology.

Kuros has attractive commercial prospects in key market segments as well as an EU hub for future clinical and distribution operations. The company is in transition to commercial stage with one product having marketing approval in the EU and US and further product expected to achieve EU approval this year. MagnetOs is approved for sale in the EU for orthopedic, spine and dental applications, and in the US for posterolateral spinal fusion. In addition, a putty formulation is being prepared for submission in the EU and the US in the second half of this year. Neuroseal, a novel biomaterial for dural sealing, is Kuros’ second product and currently under review for CE marking in the EU.

Kuros has also assembled a pipeline of clinical stage programs in various stages of development and amassed significant clinical and preclinical data in a number of indications and applications primarily in the area of orthobiologics. The Company has enrolled over 600 patients in multinational clinical trials, and has generated promising safety and efficacy in a number of significant indications.

Lists Featuring This Company

Europe, Middle East, and Africa (EMEA) Companies that Exited (Top 10K)
9,898 Number of Organizations • $921.8B Total Funding Amount • 22,386 Number of Investors
Europe, Middle East, and Africa (EMEA) Health Care Companies (Top 10K)
9,922 Number of Organizations • $163B Total Funding Amount • 19,724 Number of Investors
Medical Public Companies With Less Than $500M in Revenue
927 Number of Organizations • $156.7B Total Funding Amount • 3,656 Number of Investors
Zurich Companies With More Than 10 Employees
4,797 Number of Organizations • $18.8B Total Funding Amount • 1,993 Number of Investors

Frequently Asked Questions

Where is Kuros Biosciences's headquarters? Kuros Biosciences is located in Schlieren, Zurich, Switzerland.Who invested in Kuros Biosciences? Kuros Biosciences has 16 investors including Alpha Capital and Optiverder.How much funding has Kuros Biosciences raised to date? Kuros Biosciences has raised .When was the last funding round for Kuros Biosciences? Kuros Biosciences closed its last funding round on Sep 15, 2022 from a Post-IPO Equity round.Who are Kuros Biosciences's competitors? Alternatives and possible competitors to Kuros Biosciences may include AdaptimmuneArbutus Biopharma, and Affimed.